---
title: "Axsome Therapeutics (AXSM) news: lawsuit and settlement"
url: "https://aibio.space/companies/axsome-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "AXSM lawsuit and settlement news. Axsome Therapeutics news for investors: Axsome Therapeutics is a U.S."
---

Desk view · Opinion · Updated Oct 22, 2026

## Axsome bets on Auvelity's elderly launch to turn profitable

Axsome is growing revenue near 50% a year on Auvelity and now has a second Auvelity indication in Alzheimer's agitation. The question is whether that growth outruns rising selling costs before the next wave of phase 3 readouts, starting with ENGAGE in the fourth quarter.

Read the full desk view

aibio.space Investor Rank · Opinion

**7** /10 Positive view

Revenue is growing near 50% on Auvelity with a second indication, but one drug makes about 83% of product revenue, losses persist and cash is thin.

- **Technology**: 2/2

- **Odds**: 1/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Known molecules, new uses.** Auvelity, solriamfetol and reboxetine are being extended into new psychiatric and neurological diseases.

- **Odds**: **Good on filings, mixed on trials.** AXS-12 has a May 2027 FDA date with no panel planned, while several phase 3 readouts are still ahead.

- **Balance sheet**: **Adequate but thin.** Cash was $319.9 million at June 30 against $190 million of debt (the $70 million revolver draw was repaid in July), and the company says this funds it into cash flow positivity.

- **Main risk**: **Dependence on Auvelity.** One drug made about 83% of second-quarter product revenue, and losses persist as selling costs rise.

- **Watch next**: **Two near dates.** Third-quarter results on Nov. 2 and ENGAGE binge eating data in the fourth quarter of 2026.

## Top news on Axsome

1. 2026-08-10 Legal [Axsome derivative suit dismissed in Delaware; New York case awaits ruling on motion](https://aibio.space/news/axsome-derivative-suit-dismissed-delaware-new-york-case-awaits-ruling/) Stockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed.
2. 2026-08-10 Legal [Axsome resolves all Sunosi patent suits; Symbravo case against Apotex continues](https://aibio.space/news/axsome-resolves-all-sunosi-patent-suits-symbravo-case-against-apotex/) Axsome's 10-Q says it has settled with every current Sunosi ANDA filer, the last being Aurobindo on June 2, 2026. Its Symbravo patent suit against Apotex Inc. is in fact discovery.

## Dates

**November 2, 2026**
Third-quarter 2026 results and conference call [Source](https://finviz.com/news/399698/axsome-therapeutics-to-report-third-quarter-2026-financial-results-on-november-2)

**4Q 2026**
Topline results from phase 3 ENGAGE trial of solriamfetol in binge eating disorder [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)

**May 1, 2027**
FDA target action date for AXS-12 in cataplexy in narcolepsy [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm)

**2027**
Topline results from phase 3 SUSTAIN trial of solriamfetol in shift work disorder [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)

## The money

Cash and cash equivalents of $319.9 million at June 30, 2026. Axsome says current cash is sufficient to fund anticipated operations into cash flow positivity. Debt at June 30: $120.0 million term loans and $70.0 million revolver (the revolver was repaid in July). [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)

Second-quarter 2026 total net product revenue of $218.4 million, up 46%: Auvelity $180.3 million, Sunosi $35.8 million, Symbravo $2.3 million. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)

## Risks on the record

- Axsome remains loss-making: the second-quarter 2026 net loss was $51.3 million, with SG&A expenses of $208.1 million. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)
- Revenue is concentrated in Auvelity, which accounted for $180.3 million of $218.4 million in second-quarter net product revenue. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)
- Axsome owed $120.0 million in term loans and $70.0 million under a revolver to Blackstone at June 30, 2026. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Axsome Therapeutics?

7 out of 10, our positive view. Revenue is growing near 50% on Auvelity with a second indication, but one drug makes about 83% of product revenue, losses persist and cash is thin. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What is Auvelity approved for?

Auvelity is approved in the U.S. for major depressive disorder in adults and, since April 30, 2026, for agitation associated with dementia due to Alzheimer's disease. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-ex99_1.htm)

### How much revenue did Axsome report in Q2 2026?

Axsome reported total net product revenue of $218.4 million in the second quarter of 2026, up 46%. Auvelity contributed $180.3 million. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)

### When is the FDA decision on AXS-12?

The FDA set a PDUFA target action date of May 1, 2027 for AXS-12 in cataplexy in narcolepsy. It does not currently plan an advisory committee meeting. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm)

### When do Sunosi generics launch?

Under settlements announced June 3, 2026, five companies can market generic Sunosi on or after March 1, 2040, or Sept. 1, 2040 if pediatric exclusivity is granted. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526254708/axsm-ex99_1.htm)

### When does Axsome report Q3 2026 earnings?

Axsome will report third-quarter 2026 results on Nov. 2, 2026 before the U.S. market opens and host a call at 8:00 a.m. ET. [Source](https://finviz.com/news/399698/axsome-therapeutics-to-report-third-quarter-2026-financial-results-on-november-2)

### What is the latest Axsome Therapeutics (AXSM) stock news?

Our latest story on Axsome Therapeutics, dated Aug 10, 2026: "Axsome derivative suit dismissed in Delaware; New York case awaits ruling on motion". Stockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed. [Source](https://aibio.space/news/axsome-derivative-suit-dismissed-delaware-new-york-case-awaits-ruling/)

### Is Axsome Therapeutics facing a lawsuit?

Our latest legal story, dated Aug 10, 2026: "Axsome derivative suit dismissed in Delaware; New York case awaits ruling on motion". Stockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/axsome-derivative-suit-dismissed-delaware-new-york-case-awaits-ruling/)

### What is Axsome Therapeutics's market cap?

We do not publish live share prices. In its annual report, Axsome Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $4.40 billion as of Jun 30, 2025. Source

### Is Axsome Therapeutics a smaller reporting company?

SEC records list Axsome Therapeutics, Inc.'s filer category as: Large accelerated filer. Source

### Where is Axsome Therapeutics headquartered?

SEC records list its business address as ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007. Source

### When does Axsome Therapeutics's fiscal year end?

Axsome Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Axsome Therapeutics last file with the SEC?

Its most recent filing in our record is a 10-Q filed 2026-08-10. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm)

### What industry is Axsome Therapeutics in?

Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source

### How can I follow Axsome Therapeutics (AXSM) news?

Press Follow on this page to add Axsome Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Axsome Therapeutics so far, in Legal. Source

## Legal and investor matters

Checked against Axsome Therapeutics filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

1. 2026-07-09 Derivative suit Delaware court dismisses Axsome stockholder derivative suit The Delaware Court of Chancery dismissed with prejudice a consolidated stockholder derivative complaint against Axsome's current directors and certain current and former officers. Plaintiffs Wickstrom and Gildea filed in September 2025 and asserted claims for breach of fiduciary duties, unjust enrichment and corporate waste, arising out of allegations similar to those in the earlier securities class action. The company was a nominal defendant. The court granted the defendants' motion to dismiss on 2026-07-09, according to the second quarter 10-Q. Delaware Court of Chancery · Case Wickstrom v. Tabuteau (consolidated with Gildea v. Tabuteau) · Status: dismissed [Axsome 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm)
2. 2026-06-03 Litigation Axsome settles last Sunosi patent case, ending all Sunosi litigation Axsome announced a settlement that resolves all outstanding patent litigation over Sunosi. In June 2026 it settled with the only remaining first-to-file generic applicant. The 10-Q says Axsome had received Paragraph IV notice letters from six other companies beginning in August 2023 and settled with each of them, so no Sunosi patent litigation remains pending. Settlement terms were not stated in the filings read. Status: settled [Axsome 8-K filed 2026-06-03 and 10-Q](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm)
3. 2026-02-26 Class action Court approves settlement of Axsome securities class action The U.S. District Court for the Southern District of New York approved a settlement of the securities class action filed against Axsome in 2022. The complaint, captioned Gru v. Axsome Therapeutics, alleged false statements about manufacturing controls and the NDA for AXS-07, now Symbravo. The court issued a Final Order and Judgment on 2026-02-26 dismissing the case with prejudice. The first quarter 10-Q does not state the settlement amount. U.S. District Court, Southern District of New York · Case In re Axsome Therapeutics, Inc. Securities Litigation (originally Gru v. Axsome Therapeutics, Inc.) · Status: settled [Axsome 10-Q for the quarter ended 2026-03-31](https://www.sec.gov/Archives/edgar/data/1579428/000119312526204274/axsm-20260331.htm)
4. 2026-02-13 Derivative suit Defendants move to dismiss Axsome SDNY derivative suit; decision pending Defendants moved on 2026-02-13 to dismiss an amended stockholder derivative complaint in the Southern District of New York, consolidated as Engel and Guterba. Plaintiffs allege breach of fiduciary duties and seek contribution under the Exchange Act, based on allegations similar to the securities class action. Axsome is a nominal defendant. The second quarter 10-Q says the motion is fully briefed and the parties await the decision. U.S. District Court, Southern District of New York · Case Engel v. Tabuteau (consolidated with Guterba v. Tabuteau) · Status: pending [Axsome 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm)
5. 2025-08-19 Litigation Apotex files generic application for Symbravo; Axsome sues in New Jersey Axsome received a Paragraph IV notice letter from Apotex on 2025-08-19 stating that Apotex had filed an ANDA for a generic version of Symbravo. Axsome responded by filing a patent infringement lawsuit against Apotex in the U.S. District Court for the District of New Jersey. The second quarter 2026 10-Q says the case remains ongoing. The filings read give no trial date. U.S. District Court, District of New Jersey · Status: pending [Axsome 8-K filed 2025-08-20 and 10-Q](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm)
6. 2025-05-08 Financing Axsome signs loan agreement with Blackstone for up to $570 million On 2025-05-08 Axsome entered a loan agreement with Blackstone affiliates providing up to $570.0 million. The package includes a $120.0 million term loan funded at closing, a $180.0 million term loan available at the company's option in two $90.0 million tranches, and a $70.0 million revolving facility. The term loan proceeds, together with cash on hand, were used to repay in full the existing Hercules Capital term loan. The term loans bear interest at Term SOFR plus 4.75% and mature five years after closing. The 8-K also reports a concurrent private placement of 140,000 common shares to Blackstone-managed funds, for gross proceeds of about $15 million. [Axsome 8-K filed 2025-05-13](https://www.sec.gov/Archives/edgar/data/1579428/000095017025069785/axsm-20250508.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Auvelity (AXS-05, dextromethorphan-bupropion) | Agitation associated with Alzheimer's disease dementia | FDA approved April 30, 2026; launched June 2026 [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-ex99_1.htm) |
| AXS-05 | Smoking cessation | Phase 3 SUMMIT; first patient dosed Aug. 2026 [Source](https://axsometherapeuticsinc.gcs-web.com/node/13246) |
| AXS-12 (reboxetine) | Cataplexy in narcolepsy | NDA accepted; PDUFA date May 1, 2027 [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm) |
| Solriamfetol | ADHD; binge eating disorder; shift work disorder; MDD with excessive sleepiness | Phase 3 (FOCUS-2, FOCUS-3, ENGAGE, SUSTAIN, CLARITY) [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm) |
| AXS-14 (esreboxetine) | Fibromyalgia | Phase 3 FORWARD [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm) |
| AXS-20 (balipodect) | Schizophrenia; Tourette syndrome | Phase 3 trial-enabling activities [Source](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm) |

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AXSM on TradingView](https://www.tradingview.com/symbols/NASDAQ-AXSM/).

## SEC filings and registration

- **SEC name**: Axsome Therapeutics, Inc.

- **CIK**: 1579428

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: AXSM (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007

- **Phone**: (212) 332-3241

- **Shares outstanding**: 52,380,818 as of 2026-08-03 (10-Q filed 2026-08-10)

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm) filed 2026-08-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-20260810.htm) filed 2026-08-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-20260715.htm) filed 2026-07-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526264047/axsm-20260605.htm) filed 2026-06-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/axsm-20260605.htm) filed 2026-06-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526254708/axsm-20260603.htm) filed 2026-06-03
- [10-Q](https://www.sec.gov/Archives/edgar/data/1579428/000119312526204274/axsm-20260331.htm) filed 2026-05-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-20260504.htm) filed 2026-05-04

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001579428), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/axsome-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Axsome Therapeutics (AXSM) news: lawsuit and settlement", 2026-10-31, https://aibio.space/companies/axsome-therapeutics/